The New England journal of medicine, 2012-03, Vol.366 (9), p.799-807
- Verstovsek, Srdan
- Mesa, Ruben A
- Gotlib, Jason
- Levy, Richard S
- Gupta, Vikas
- DiPersio, John F
- Catalano, John V
- Deininger, Michael
- Miller, Carole
- Silver, Richard T
- Talpaz, Moshe
- Winton, Elliott F
- Harvey, Jimmie H
- Arcasoy, Murat O
- Hexner, Elizabeth
- Lyons, Roger M
- Paquette, Ronald
- Raza, Azra
- Vaddi, Kris
- Erickson-Viitanen, Susan
- Koumenis, Iphigenia L
- Sun, William
- Sandor, Victor
- Kantarjian, Hagop M
2012
Details
- Autor(en) / Beteiligte
- Verstovsek, Srdan
- Mesa, Ruben A
- Gotlib, Jason
- Levy, Richard S
- Gupta, Vikas
- DiPersio, John F
- Catalano, John V
- Deininger, Michael
- Miller, Carole
- Silver, Richard T
- Talpaz, Moshe
- Winton, Elliott F
- Harvey, Jimmie H
- Arcasoy, Murat O
- Hexner, Elizabeth
- Lyons, Roger M
- Paquette, Ronald
- Raza, Azra
- Vaddi, Kris
- Erickson-Viitanen, Susan
- Koumenis, Iphigenia L
- Sun, William
- Sandor, Victor
- Kantarjian, Hagop M
- Titel
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- Ist Teil von
- The New England journal of medicine, 2012-03, Vol.366 (9), p.799-807
- Ort / Verlag
- Waltham, MA: Massachusetts Medical Society
- Erscheinungsjahr
- 2012
- Link zum Volltext
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- This trial showed clinically significant responses in spleen size and quality of life among patients with myelofibrosis receiving ruxolitinib, a JAK1 and JAK2 inhibitor. The agent has some myelotoxicity, but this study showed a survival advantage with ruxolitinib. Myelofibrosis, a myeloproliferative neoplasm, is manifested by abnormal blood counts (anemia, thrombocytosis or thrombocytopenia, and leukocytosis or leukopenia), splenomegaly, and debilitating symptoms (e.g., fatigue, weakness, abdominal pain, cachexia, weight loss, pruritus, night sweats, and bone pain), which are thought to be caused by the combined effects of massive splenomegaly and elevated levels of proinflammatory cytokines. 1 Survival ranges from approximately 2 to 11 years, depending on defined prognostic factors. 2 Traditional therapeutic options, including splenectomy, have limited benefit. 3 Although allogeneic stem-cell transplantation may cure myelofibrosis, few patients are eligible for this treatment. Although the gain-of-function mutation in the gene encoding Janus kinase . . .
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1110557Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4822164
- Format
- –
- Schlagworte
- Acute myeloid leukemia, Adult, Aged, Aged, 80 and over, Anemia, Biological and medical sciences, Blood platelets, Cell Transformation, Neoplastic, Clinical significance, Clinical trials, Cytokines, Dose-response relationship (Biochemistry), Double-Blind Method, Double-blind studies, Drug therapy, Drugs, Enzyme inhibitors, Female, Follow-Up Studies, General aspects, Hematologic and hematopoietic diseases, Humans, Intention to Treat Analysis, Janus kinase, Janus Kinase 1 - antagonists & inhibitors, Janus Kinase 2 - antagonists & inhibitors, Kaplan-Meier Estimate, Kinases, Leukemia, Myeloid, Acute - mortality, Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis, Magnetic resonance imaging, Male, Medical research, Medical sciences, Medical treatment, Middle Aged, Myelofibrosis, Myeloid leukemia, Nitriles, Organ Size, Patients, Primary Myelofibrosis - drug therapy, Primary Myelofibrosis - mortality, Primary Myelofibrosis - pathology, Product/Service Evaluations, Protein Kinase Inhibitors - adverse effects, Protein Kinase Inhibitors - therapeutic use, Pyrazoles - adverse effects, Pyrazoles - therapeutic use, Pyrimidines, Quality of Life, Spleen, Spleen - drug effects, Spleen - pathology, Splenomegaly - drug therapy, Survival, Thrombocytopenia